Amgen and Allergan’s ABP 980 (biosimilar, Herceptin) Receives CHMP Recommendation for Three Types of Cancer

 Amgen and Allergan’s ABP 980 (biosimilar, Herceptin) Receives CHMP Recommendation for Three Types of Cancer

Amgen and Allergan Report Results of ABP 798 (rituximab, biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

Shots:

  • The CHMP recommendation is based on P-III study results assessing ABP 980 in adult female patients with HER2-positive early breast cancer
  • The P-III study resulted in analytical, PK, pharmacology, toxicology data with efficacy, safety and immunogenicity in patients
  • ABP 980 (trastuzumab) is a recombinant DNA-derived mIgG1 kappa Ab indicated for HER2-overexpressing early BC, adjuvant BC, mBC and metastatic gastric cancer. In Dec, 2011 Amgen & Allergan formed a collaboration to develop & commercialize four oncology Ab biosimilars

Click here read full press release/ article | Ref: Amgen | Image: Thailand Medical News

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post